1. Versican: Role in Cancer Tumorigenesis
    Paul A. Keire et al, 2017, Extracellular Matrix in Tumor Biology CrossRef
  2. Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review
    Holly Butler et al, 2022, Carcinogenesis CrossRef
  3. Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer
    Naoki Kawahara et al, 2017, Biomedical Reports CrossRef
  4. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
    Satoe Fujiwara, 2023, Japanese Journal of Clinical Oncology CrossRef
  5. Next-Generation Intelligent MXene-Based Electrochemical Aptasensors for Point-of-Care Cancer Diagnostics
    Arpana Parihar et al, 2022, Nano-Micro Letters CrossRef
  6. Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary (Review)
    Hiroshi Kobayashi et al, 2018, Biomedical Reports CrossRef
  7. Serum Free Fatty Acid Changes Caused by High Expression of Stearoyl-CoA Desaturase 1 in Tumor Tissues Are Early Diagnostic Markers for Ovarian Cancer
    Kanoko Katoh et al, 2023, Cancer Research Communications CrossRef

  8. An AFM-Based Nanomechanical Study of Ovarian Tissues with Pathological Conditions


    Arian Ansardamavandi et al, 2020, International Journal of Nanomedicine CrossRef
  9. Endometriosis and Endometriosis-Associated Ovarian Cancer (EAOC)
    Tanja Pejovic et al, 2020, Hormonal Pathology of the Uterus CrossRef
  10. Reciprocal links between venous thromboembolism, coagulation factors and ovarian cancer progression
    Nathalie Swier et al, 2017, Thrombosis Research CrossRef
  11. Napsin A, Hepatocyte Nuclear Factor-1-Beta (HNF-1β), Estrogen and Progesterone Receptors Expression in Arias-Stella Reaction
    Philip P.C. Ip et al, 2019, American Journal of Surgical Pathology CrossRef
  12. Napsin-A, a Possible Diagnostic Marker for Differentiating Clear Cell Ovarian Carcinoma From Other High-grade Ovarian Carcinomas
    Hanan A. Alshenawy et al, 2018, Applied Immunohistochemistry & Molecular Morphology CrossRef
  13. E-Cadherin repression increases amount of cancer stem cells in human A549 lung adenocarcinoma and stimulates tumor growth
    M. Farmakovskaya et al, 2016, Cell Cycle CrossRef
  14. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma
    Noriaki Arakawa et al, 2016, PLOS ONE CrossRef
  15. Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary
    Etsuko Miyagi et al, 2021, International Journal of Clinical Oncology CrossRef
  16. Toward an understanding of tissue factor pathway inhibitor‐2 as a novel serodiagnostic marker for clear cell carcinoma of the ovary
    Hiroshi Kobayashi et al, 2021, Journal of Obstetrics and Gynaecology Research CrossRef
  17. Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis
    Joana G. Rodrigues et al, 2018, Cellular Immunology CrossRef
  18. Multi-modal Profiling of the Extracellular Matrix of Human Fallopian Tubes and Serous Tubal Intraepithelial Carcinomas
    Carine Renner et al, 2022, Journal of Histochemistry & Cytochemistry CrossRef
  19. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
    Chenchen Zhu et al, 2021, BMC Cancer CrossRef
  20. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy
    Katharina Wiedemeyer et al, 2020, Human Pathology CrossRef
  21. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
    Zesi Liu et al, 2024, Journal of Ovarian Research CrossRef
  22. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
    Wen Li et al, 2016, Drug Resistance Updates CrossRef